Catalogue

Background
The p63 protein, a homologue of the tumour-suppressor p53, is highly expressed in the nuclei of basal or progenitor layer of many epithelial tissues. p63 is detected in prostate basal cells in normal prostate glands and PIN. Other markers for basal cells are high molecular cytokeratins (CK 1, 5, 10 and 14), which can be labelled with HMW CK clone 34ßE12. In prostate adenocarcinoma basal cells disappear and staining with both p63 and HMW CK fails. Thus the combination of p63 and HMW CK is a useful tool as differential markers for benign prostate glands and adenocarcinoma (negative marker). nuclear p63 and cytoplasmic high molecular weight cytokeratins.

Source

Immunogen: Recombinant human p63 protein (aa 1-205) and cytokeratin extract of human stratum corneum

Product
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for 250-500 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if desired.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for 250-500 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if desired.

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005), but also other staining systems including anti-mouse IgG will be suitable

Specificity

Species Reactivity: Human

Applications
IHC(P)

Incubation Time: 30-60 min

Working Concentration: (RTU) neat

Pre-Treatment: Use formalin-fixed and paraffin-embedded sections; Retrieval conditions: Unmasking fluid T, TEC buffer (Tris/EDTA/Citrate) pH 8 (Art. No. DE005) in a pressure cooker at 100°C 20-40 minutes

Positive Control: Normal prostate tissue or skin

Storage
2-8°C

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Signoretti S., Waltregny D., Dilks J., Isaak B., Lin D., Garraway L., et al. (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J. Pathol. 157; 1769-1775. 2. Weinstein M.H., Signoretti S., and Loda M. (2002) Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 15(12); 1302-1308 3. Yang X.J., Lecksell K., Gaudin P., and Epstein J.I. (1999) Rare expression of high-molekular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am. J. Surg. Pathol. 23(2); 147-152. 4. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec;35(12):1462-8. 5. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005 Feb;123(2):231-6.

Safety Datasheet(s) for this product: